Is there value in liver function test and creatine phosphokinase monitoring with statin use?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Cardiology

• Publication date

  2004-11-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2004.07.052PMID 15519289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lovastatin-induzierte akute cholestatische Hepatitis

  2008cited by this paper
• Cholestatischer Ikterus während Lovastatin-Einnahme

  2008cited by this paper
• HMG-CoA reductase inhibitors

  2007cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Are patients with elevated liver tests at increased risk of drug-induced liver injury?

  2004cited by this paper
• Intensive statin therapy--a sea change in cardiovascular prevention.

  2004cited by this paper
• Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

  2004cited by this paper
• Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians

  2004cited by this paper
• Serum Total Cholesterol Concentrations and Awareness, Treatment, and Control of Hypercholesterolemia Among US Adults: Findings From the National Health and Nutrition Examination Survey, 1999 to 2000

  2003cited by this paper
• The liver and lovastatin.

  2002cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• Cerivastatin and reports of fatal rhabdomyolysis.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force

  2002cited by this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002cited by this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Drug-induced liver disease.

  2000cited by this paper
• Fatty Infiltration of Liver in Hyperlipidemic Patients

  2000cited by this paper
• Defining patient risks from expanded preventive therapies.

  2000cited by this paper
• Schiff's diseases of the liver

  1999cited by this paper
• [Hepatitis associated with treatment with lovastatin. Presentation of 2 cases].

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• [Lovastatin-induced acute cholestatic hepatitis].

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

  1994cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• Guide to clinical preventive services: a challenge to physician resourcefulness

  1993cited by this paper
• Lovastatin and cholestasis.

  1993cited by this paper
• Lovastatin-induced hepatitis.

  1992cited by this paper
• HMG CoA reductase inhibitors

  1992cited by this paper
• [Cholestatic jaundice during lovastatin medication].

  1991cited by this paper
• Cholestatic jaundice associated with lovastatin (Mevacor) therapy.

  1990cited by this paper
• Cholestatic jaundice associated with lovastatin (mevacor) therapy

  1990cited by this paper
• Drug treatment of dyslipoproteinemia.

  1990cited by this paper
• Cholestatic jaundice associated with lovastatin (mevacor) therapy.

  1990cited by this paper
• Drug-Induced Liver Disease

  1978cited by this paper

• Risk Factors Analysis of Severe Liver Injury Induced by Statins

  2023cites this paper
• A STUDY OF THE PROGNOSTIC SIGNIFICANCE OF SERUM CREATINE PHOSPHOKINASE LEVEL IN ORGANOPHOSPHORUS COMPOUND POISONING PATIENTS

  2023cites this paper
• Serum creatinine phosphokinase: A potential prognostic marker in assessing clinical severity with organophosphorus poisoning

  2023cites this paper
• Initial Serum Creatine Phosphokinase Level as an Indicator of Severity and Prognosis of Acute Organophosphorus Poisoning - A Retrospective Clinical Study

  2022cites this paper
• Severe Liver Injury Associated With High-Dose Atorvastatin Therapy

  2021cites this paper
• Drug-Induced Liver Injury from Statins.

  2020cites this paper
• 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.

  2019cites this paper
• Management of Dyslipidemia

  2018cites this paper
• Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice

  2018cites this paper
• Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

  2017cites this paper
• Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity

  2017cites this paper
• Creatinephosphokinase in organophosphorus poisoning

  2017cites this paper
• Acute toxicological studies of leaf extracts of Morus indica L. in rats

  2016cites this paper
• [Part II. Combination statin plus fibrate regimens (free and fixed)].

  2016cites this paper
• Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation

  2015cites this paper
• "ESTATINAS, MIOPATIA E EXERCÍCIO FÍSICO"

  2014cites this paper
• Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope

  2014cites this paper
• Alanine Aminotransferase-Old Biomarker and New Concept: A Review

  2014cites this paper
• Correlation between Serum Creatine Phosphokinase and Severity of Acute Organophosphorus Poisoning: A Prospective Clinical Study (2012-2013)

  2013cites this paper
• Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways

  2013cites this paper
• Tratamiento combinado con fenofibrato. Seguridad

  2012cites this paper
• 13 – Hepatic injury due to drugs, herbal compounds, chemicals and toxins

  2012cites this paper
• Is there clinical benefit to routine enzyme testing of patients on statins?

  2012cites this paper
• Clinical Perspective: Statins and the Liver—Harmful or Helpful?

  2012cites this paper
• Toxicity Screening and Hypocholesterolemic Effect Evaluation of Aqueous Extract of Anacardium occidentale Linn. in Hypercholesterolemic Induced Rabbits

  2011cites this paper
• Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance

  2011cites this paper
• Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists

  2010cites this paper
• Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?

  2009cites this paper
• Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.

  2009cites this paper
• Towards companion diagnostics for the management of statin therapy.

  2009cites this paper
• Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation.

  2009cites this paper
• Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use

  2009cites this paper
• Adverse effects of statins - mechanisms and consequences.

  2009cites this paper
• Relationship of ethnic origin, gender, and age to blood creatine kinase levels.

  2009cites this paper
• Carcinoma da bexiga num modelo animal experimental : efeito preventivo de uma estatina

  2009cites this paper
• Statins and stroke.

  2008cites this paper
• Review article: the use of potentially hepatotoxic drugs in patients with liver disease

  2008cites this paper
• Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

  2008cites this paper
• Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem

  2008cites this paper
• Drug-Induced Liver Injury: Review Article

  2007cites this paper
• Review article: drug hepatotoxicity

  2007cites this paper
• Statins and Monitoring of Liver Function Tests

  2007cites this paper
• Myotoxicity associated with lipid-lowering drugs

  2007cites this paper
• Inactivation of thiolase by 2-alkynoyl-CoA via its intrinsic isomerase activity.

  2007cites this paper
• Liv.52 DS Tablets Evaluation of Liv.52 DS tablet as a hepatoprotective agent in prophylaxis with statin therapy

  2007cites this paper
• Statins and Hepatotoxicity

  2007cites this paper
• An assessment of statin safety by hepatologists.

  2006cites this paper
• Drug Insight: statins and gastrointestinal cancer

  2006cites this paper
• American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively

  2006cites this paper
• Fluvastatin and Hepatic Reactions

  2006cites this paper
• Statin safety: an overview and assessment of the data--2005.

  2006cites this paper
• Primary Evaluation and Management of Statin Therapy Complications

  2006cites this paper
• [Acute cholestatic hepatitis after atorvastatin reintroduction].

  2006cites this paper
• Statins in the intensive care unit

  2006cites this paper
• Hepatitis colestásica aguda tras la reintroducción de atorvastatina

  2006cites this paper
• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

  2005cites this paper
• A Descriptive Evaluation of Routine Complete Blood Count Monitoring in Patients Receiving Anticoagulation Therapy

  2005cites this paper
• Statin-induced myositis: a commonly encountered or rare side effect?

  2005cites this paper
• Lipids for Psychiatrists - an overview

  2005cites this paper
• Drug-induced liver disease 2004

  2005cites this paper
• Safety of statins: effects on muscle and the liver.

  2005cites this paper